Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 |
| clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06748755 | A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard | active not recruiting | — | 90 | Superior UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06751108 | Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients | active not recruiting | — | 2,000 | Seoul National UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | active not recruiting | Phase 2 | 118 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03875573 | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:(Neo-CheckRay) | active not recruiting | Phase 2 | 147 | Jules Bordet InstituteOTHER | 2 | Dec 20, 2024 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04926766 | Super Hypofractionated Irradiation for Whole Breast Treatment(SHIFT) | active not recruiting | N/A | 217 | Ruijin HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06744140 | Role of MRI Breast in Detection of Ductal Carcinoma in Situ | active not recruiting | — | 35 | Superior UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03616886 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC(SYNERGY) | active not recruiting | Phase 1 / Phase 2 | 129 | Jules Bordet InstituteOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT06741423 | Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics | active not recruiting | — | 600 | Heidelberg UniversityOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT00798070 | Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients(PANTHER) | active not recruiting | Phase 3 | 2,017 | Karolinska University HospitalOTHER | 3 | Dec 18, 2024 | clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03595787 | COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome(COHABILIT) | active not recruiting | N/A | 50 | Institut Paoli-CalmettesOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT04487717 | Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer(PREDICT) | active not recruiting | — | 581 | Novomics. Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04507841 | Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 67 | Tongji HospitalOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04910308 | RAdiotherapy With FDG-PET Guided Dose-PAINTing for Primary Head and Neck(RADPAINT-2) | active not recruiting | N/A | 10 | Oslo University HospitalOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02642471 | Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010) | active not recruiting | N/A | 1,080 | Sun Yat-sen UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT01531595 | Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer(AXOAXI) | active not recruiting | Phase 2 | 100 | Pia OsterlundOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02430103 | Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients | active not recruiting | — | 349 | Peking University People's HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02515760 | Tumor-specific T Cells in Lung Cancer | active not recruiting | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04794010 | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 825 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06082882 | Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2(SEMM2) | active not recruiting | N/A | 8,000 | The University of Texas Health Science Center, HoustonOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730035 | PRediction of Outcomes and PERsonalized Radiotherapy by Biomarkers and Functional Imaging | active not recruiting | N/A | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02999074 | Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy(BENEFIT) | active not recruiting | N/A | 183 | German Cancer Research CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT04195139 | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM(NUTMEG) | active not recruiting | Phase 2 | 103 | University of SydneyOTHER | 2 | Dec 11, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06727357 | Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP | active not recruiting | Phase 2 | 38 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | active not recruiting | Phase 1 | 36 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03385226 | A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)(PORT) | active not recruiting | Phase 2 | 46 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases(STORM) | active not recruiting | Phase 2 | 196 | University Hospital, GhentOTHER | 6 | Dec 9, 2024 | clinicaltrials |
| NCT04726787 | RadiothErapy priMIng for CAR-T(REMIT) | active not recruiting | N/A | 6 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04811846 | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | active not recruiting | N/A | 40 | University Teaching Hospital Hall in TirolOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722300 | Clinical Study on the Impact of Eradication of Oral Porphyromonas Gingivalis on the Prognosis of Early Esophageal Cancer After ESD Surgery | active not recruiting | N/A | 856 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06723496 | Psychiatric Problems in Children With Acute Lymphoblastic Leukemia and Their Caregivers | active not recruiting | — | 90 | Assiut UniversityOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02221778 | SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE | active not recruiting | Phase 2 | 25 | University of Sao PauloOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02315716 | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma(Cardamon) | active not recruiting | Phase 2 | 281 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03379428 | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | US Oncology ResearchINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04565769 | Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Aarhus University HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | active not recruiting | — | 2,001 | Yuhan CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Dec 27, 2024source: clinicaltrials